Zenotech Laboratories

Zenotech Laboratories Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Zenotech Laboratories (532039.BO) as of Nov 22, 2026 is -951.85 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 169.05 % — a change of -663.07% (lower).

Cash Conversion

-951.85 %

YoY

-663.07%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Zenotech Laboratories is 2026 -951.85 % . Cash Conversion Rate (OCF/Net Income) of Zenotech Laboratories was 2025 169.05 % . It decreases by -663.07% lower compared to the previous year.

The Zenotech Laboratories Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2019
449.10 INR
Jan 1, 2020
105.58 INR
Jan 1, 2021
-472.47 INR
Jan 1, 2022
79.67 INR
Jan 1, 2023
178.37 INR
Jan 1, 2024
142.46 INR
Jan 1, 2025
169.05 INR
Jan 1, 2026
-951.85 INR
The Zenotech Laboratories Cash Conversion history
YEARCash ConversionYoY
-951.85 %-663.07%
169.05 %+18.66%
142.46 %-20.13%
178.37 %+123.88%
79.67 %-116.86%
-472.47 %-547.48%
105.58 %-76.49%
449.10 %+227.50%
137.13 %-1,764.69%
-8.24 %-132.85%
25.08 %-34.76%
38.44 %-36.88%
60.90 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zenotech Laboratories Stock analysis

What does Zenotech Laboratories do? Zenotech Laboratories Ltd manufactures and markets pharmaceutical products, specializing in oncology, biotechnology, and general injectables. The company operates from a manufacturing facility in Turkapally village, Shamirpet Mandal, Telangana, producing specialty generic injectables for the pharmaceutical sector. Its products are sold to healthcare providers and distributors within the pharmaceutical industry, targeting markets that require specialized injectable solutions. The firm's business model focuses on the production and distribution of generic injectables, leveraging its facility in Telangana to serve both domestic and international markets. By concentrating on oncology and biotechnology injectables, Zenotech addresses specific medical needs, generating revenue through the sale of these high-demand pharmaceutical products to hospitals, clinics, and pharmaceutical distributors. Zenotech Laboratories Ltd's revenue streams come from the sale of its specialty generic injectables, including oncology and biotechnology products, to healthcare institutions and distribution networks. The company's manufacturing capabilities in Telangana support its role as a supplier in the pharmaceutical supply chain, with a focus on injectable formulations that cater to critical healthcare applications. Zenotech Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zenotech Laboratories stock

Cash Conversion Rate (OCF/Net Income) of Zenotech Laboratories is -951.85 % in 2026.

Cash Conversion Rate (OCF/Net Income) of Zenotech Laboratories changed from 169.05 % to -951.85 %, representing a -663.07% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Zenotech Laboratories since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Zenotech Laboratories with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Zenotech Laboratories

All Key Metrics — Zenotech Laboratories